United Therapeutics Corp UTHR

NAS: UTHR | ISIN: US91307C1027   31/05/2024
275,13 USD (+1,73%)
(+1,73%)   31/05/2024

3 november 2021 · United Therapeutics Corporation Reports Third Quarter 2021 Financial Results · Persbericht

1 november 2021 · United Therapeutics Corporation To Present At The Credit Suisse 30th Annual Healthcare Conference · Persbericht

27 oktober 2021 · United Therapeutics Corporation To Report Third Quarter 2021 Financial Results Before The Market Opens On Wednesday, November 3, 2021 · Persbericht

21 oktober 2021 · United Therapeutics Details New Data Presented at CHEST Annual Meeting 2021 · Persbericht

18 oktober 2021 · United Therapeutics Provides an Update on the Progress of the Tyvaso DPI™ New Drug Application · Persbericht

11 oktober 2021 · United Therapeutics to Present New Data at CHEST Annual Meeting 2021 · Persbericht

30 september 2021 · United Therapeutics Converts to a Public Benefit Corporation Following Shareholder Approval · Persbericht

10 september 2021 · United Therapeutics Releases its Annual Corporate Responsibility Report · Persbericht

7 september 2021 · United Therapeutics Presents Tyvaso DPI™ BREEZE Clinical Data At The European Respiratory Society International Congress 2021 · Persbericht

25 augustus 2021 · United Therapeutics Partners with Former NFL Player Devon Still and His Daughter Leah to Launch "Braving NeuroBLASToma" in Honor of Childhood Cancer Awareness Month · Persbericht

24 augustus 2021 · United Therapeutics to Present Tyvaso DPI™ BREEZE Clinical Data at the European Respiratory Society International Congress 2021 · Persbericht

4 augustus 2021 · United Therapeutics Corporation Reports Second Quarter 2021 Financial Results · Persbericht

3 augustus 2021 · United Therapeutics Corporation To Present At The 2021 Wedbush PacGrow Healthcare Virtual Conference · Persbericht

28 juli 2021 · United Therapeutics Corporation To Report Second Quarter 2021 Financial Results Before The Market Opens On Wednesday, August 4, 2021 · Persbericht

30 juni 2021 · United Therapeutics Announces The Lancet Respiratory Medicine Publication Of Post-Hoc Analysis Of FVC Change From The Tyvaso® INCREASE Study · Persbericht

16 juni 2021 · MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI™ With New Drug Application Acceptance From The FDA · Persbericht

16 juni 2021 · United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review · Persbericht

7 juni 2021 · United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia · Persbericht

3 juni 2021 · United Therapeutics Announces First Patient Enrolled In Phase 3 TETON Study Of Tyvaso In Patients With Idiopathic Pulmonary Fibrosis · Persbericht

25 mei 2021 · United Therapeutics Corporation To Present At The Jefferies Virtual Healthcare Conference · Persbericht

Mijn selecties